Navigation Links
Archemix in Medical News

Alexandria Real Estate Equities Provides Update

...ical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., archemix Corp., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; and the remainder of approximately 7% was comprised of traditional ...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...icology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and archemix Corp. Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, acros...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...ction with Roche. * Isis licensed technology to archemix for aptamer drug applications in exchange for...s and royalties on aptamer drugs developed by archemix that incorporate Isis' proprietary chemistries or ...sis received the first milestone payment from archemix for the advancement of Archemix' aptamer drug into...
Archemix in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...velop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature. Isis earned milestone payments from archemix and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interfe...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - archemix Corp., a biotechnology company focused on discover...n as thrombotic thrombocytopenic purpura, or TTP. archemix plans to present a complete data set from this Pha...esized rather than biologically expressed. About archemix ...
Archemix in Biological Technology

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...Biotech IPOs on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...

Biotech Drops Amid Tough Markets in February

...otech IPOs remain on hold The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...
Other Tags
(Date:5/5/2015)... (PRWEB) May 05, 2015 Private equity ... FZ LLC has announced that its dental stem cell ... Store-A-Tooth™ increased once again--in April, 2015 –and posted yet ... of increased record volume and represents a significant 54% ... dental stem cell biobank is conducted via the Store-A-Tooth ...
(Date:5/5/2015)... Indian Trail, NC (PRWEB) May 05, 2015 ... firm serving Indian Trail, Monroe, Matthews, Charlotte and surrounding ... in the field of accounting. This company provides assistance ... a priority as they prepare individual or corporate tax ... a system in the cloud that allows clients (and ...
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... 05, 2015 Hiliary Critchley, Senior ... present at the 24th Annual WEDI National ... MT in Scottsdale, AZ. WEDI, the Workgroup for ... authority on the use of health IT to ... National Director of Telemedicine for UnitedHealthcare will co-present ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... ) filed on behalf of men who ... their use of prescription testosterone replacement therapies ... multidistrict litigation underway in U.S. District Court, ... documents dated May 1st, defendants AbbVie, Inc., ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
Other Contents